Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tizanidine plus long-acting stimulant versus stimulant plus placebo in resistant ADHD
IRCT20230619058530N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of tizanidine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Severity of ADHD at month 2. Started Oct 2023; status: completed.
02
Drugs
tizanidine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20230619058530N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230619058530N2.